Eisai(OTC) ESAIY

Current Price$7.10

Market Cap$8.01B

Since IPO (2023)-54%

5 Year-91%

1 Year+2%

1 Month+19%

Eisai last closing stock price
Metric	Price	Date
Last close	USD 7.10	2026-07-24

Eisai stock price return by period
Period	Price return	Price at period start	Period start date
1 week	+3.95%	USD 6.83	2026-07-17
1 month	+18.73%	USD 5.98	2026-06-24
3 month	-3.53%	USD 7.36	2026-04-24
Year to date	-3.79%	USD 7.38	2025-12-31
1 year	+2.13%	USD 6.95	2025-07-24
3 year	-51.87%	USD 14.75	2023-07-25
5 year	-90.61%	USD 75.58	2021-07-23
Since inception	-54.25%	USD 15.52	2023-02-02

Eisai Financials at a Glance

Market Cap

$8.01B

Revenue (TTM)

¥837.01B

Net Income (TTM)

¥39.02B

EPS (TTM)

$0.23

P/E Ratio

30.83

Dividend

$0.25

Beta (Volatility)

0.25 (Low)

Dividend

$0.25

Beta (Volatility)

0.25 (Low)

Price

$7.10

Volume

61,107

Open

$7.09

Price

$7.10

Volume

61,107

Open

$7.09

Previous Close

$7.10

Daily Range

$7.07 - $7.11

52-Week Range

$5.69 - $9.22

Estimated Earnings Date

May 13, 2026

Dividend

$0.25

Beta (Volatility)

0.25 (Low)

Price

$7.10

Volume

61,107

Open

$7.09

Previous Close

$7.10

Daily Range

$7.07 - $7.11

52-Week Range

$5.69 - $9.22

Estimated Earnings Date

May 13, 2026

ESAIY News

Medical personnel preparing an injection.

What Are the Clinical Development Phases?

Benjamin LockeAug 16, 2025

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Eisai

Eisai Co., Ltd. is a Japanese pharmaceutical company engaged in the full lifecycle of drug development, from research to distribution. The firm specializes in innovative treatments, particularly in oncology and neurology, with a strong commitment to improving patient outcomes.

Products and Services

Dayvigo for insomnia management
Lenvima, an anticancer therapy for multiple cancers
Aricept, a treatment for Alzheimer's disease

Growth Outlook

Recent partnerships enhance product pipeline and market reach
Focus on oncology and neurology expected to drive future growth
Investment in R&D aims to expand therapeutic offerings

Financial Highlights

TTM revenue of 1.01 trillion JPY, reflecting strong market demand
Net income of 17.49 billion JPY in Q3 2025, indicating profitability
Dividend yield of 4.02%, appealing for income-focused investors

Eisai Co., Ltd. has established itself as a key player in the pharmaceutical industry, particularly in the development of innovative therapies. The company's focus on oncology and neurology positions it well for future growth, supported by strategic partnerships and a robust product pipeline. Recent financial performance highlights a significant revenue stream and profitability, making it an attractive option for potential investors. The commitment to research and development further underscores the company's dedication to advancing healthcare solutions.

AI Generated • Jun 26, 2026

Industry

Pharmaceuticals

Sector

Health Care

Employees

10,543

CEO

Haruo Naito

Website

www.eisai.co.jp/index.html

Headquarters

Tokyo, TY 112-8088, JP

ESAIY Financials

Key Financial Metrics (TTM)

Gross Margin

76.83%

Operating Margin

4.87%

Net Income Margin

4.67%

Return on Equity

4.44%

Return on Capital

4.05%

Return on Assets

2.66%

Earnings Yield

3.24%

Dividend Yield

3.58%

Payout Ratio

1.17%

Stock Overview

Market Cap

$8.01B

Shares Outstanding

1.13B

Volume

61.11K

Avg. Volume

231.29K

Financials (TTM)

Gross Profit

¥643.02B

Operating Income

¥40.59B

EBITDA

¥93.34B

Operating Cash Flow

¥62.57B

Capital Expenditure

-¥15.37B

Free Cash Flow

¥47.20B

Cash & ST Invst.

¥246.49B

Total Debt

¥186.89B

Eisai Performance Analysis

Eisai annual revenue and year-over-year revenue growth by fiscal year
Fiscal year	Period end	Revenue	YoY growth
2023	2023-03-31	JPY 5,495,248,038	-18.3%
2024	2024-03-31	JPY 5,136,302,320	-6.5%
2025	2025-03-31	JPY 5,178,078,719	0.8%
2026	2026-03-31	JPY 5,477,248,525	5.8%

Eisai sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q1	2025-06-30	13.1%
Q2	2025-09-30	-1.1%
Q3	2025-12-31	11.5%
Q4	2026-03-31	-6.6%

Eisai annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal year	Period end	Diluted EPS	YoY growth
2023	2023-03-31	JPY 0.36	-4.1%
2024	2024-03-31	JPY 0.26	-28.2%
2025	2025-03-31	JPY 0.27	4.9%
2026	2026-03-31	JPY 0.23	-15.5%

Eisai sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q1	2025-06-30	1480.5%
Q2	2025-09-30	-29.6%
Q3	2025-12-31	69.3%
Q4	2026-03-31	-119.0%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name

Q4 2025YOY CHG

Revenue

¥209.20B

+16.5%

Gross Profit

¥156.23B

+10.9%

Gross Margin

74.68%

N/A

Market Cap

$8.01B

N/A

Market Cap/Employee

$759.94K

N/A

Employees

10,543

N/A

Net Income

-¥3.31B

-465.4%

EBITDA

-¥85.54M

-100.8%

Quarterly Fundamentals

Name

Q4 2025YOY CHG

Total Cash

¥246.49B

-7.4%

Total Debt

¥186.89B

-0.3%

Accounts Receivable

¥227.99B

+3.6%

Inventory

¥258.66B

+19.8%

Long Term Debt

¥135.36B

+35.6%

Short Term Debt

¥51.53B

-41.2%

Return on Assets

2.66%

N/A

Return on Invested Capital

3.63%

N/A

Free Cash Flow

-¥2.20B

-108.9%

Operating Cash Flow

¥2.86B

-89.7%

Other Investments to Explore

People Also Watch

SymbolSymbol / CompanyCompanyPricePrice Chg

KYKOFKyowa Kirin Co., Ltd.

KYKOFKyowa Kirin Co., Ltd.$14.43+0.00%

WILYYDemant A/S

WILYYDemant A/S$20.66+0.00%

WILLFDemant A/S

WILLFDemant A/S$41.51+0.00%

GIFLFGrifols, S.A.

GIFLFGrifols, S.A.$10.25+0.00%

BIOVFSwedish Orphan Biovitrum AB (publ)

BIOVFSwedish Orphan Biovitrum AB (publ)$49.03+0.00%

Trending Stocks

SymbolSymbol / CompanyCompanyPricePrice Chg

NOKNokia

NOKNokia$9.10-0.06%

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares$7.42-0.04%

ONDSOndas

ONDSOndas$7.80-0.02%

SOFISoFi Technologies

SOFISoFi Technologies$16.46-0.01%

TAT&T

TAT&T$24.13+0.05%

FFord Motor Company

FFord Motor Company$14.37+0.02%

AALAmerican Airlines Group

AALAmerican Airlines Group$14.48+0.07%

Questions About ESAIY

What is the current price of Eisai?

Eisai is trading at $7.10 per share.

What is the 52-week range for Eisai?

Over the past 52 weeks, Eisai has traded between $5.69 and $9.22.

How much debt does Eisai have?

As of the most recent reporting period, Eisai reported total debt of ¥1.44B.

How much cash does Eisai have on hand?

Eisai reported ¥1.54B in cash and cash equivalents in its most recent financial results.

What is Eisai’s dividend yield?

Eisai currently has a dividend yield of 3.58%.

Eisai(OTC) ESAIY

Eisai Financials at a Glance

ESAIY News

What Are the Clinical Development Phases?

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

About Eisai

ESAIY Financials

Key Financial Metrics (TTM)

Stock Overview

Financials (TTM)

Eisai Performance Analysis

Revenue Growth Rate

Earnings Per Share Growth Rate

Quarterly Performance

Quarterly Fundamentals

Other Investments to Explore

People Also Watch

Trending Stocks

Questions About ESAIY

What is the current price of Eisai?

What is the 52-week range for Eisai?

How much debt does Eisai have?

How much cash does Eisai have on hand?

What is Eisai’s dividend yield?

Premium Investing Services